| Overview |
| bs-19506R-RBITC |
| NUDCD1 Polyclonal Antibody, RBITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Dog, Cow, Sheep, Horse, Rabbit, Zebrafish |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NUDCD1 |
| 431-530/583 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 84955 |
| Q96RS6 |
| Nucleus |
| 4921532K09Rik; AA407246; AW260430; AW556235; Chronic myelogenous leukemia tumor antigen 66; CML66; CML66 L; FLJ14991; NudC domain containing 1; NudC domain-containing protein 1; NUDC1_HUMAN; nudcd1; OVA66; RGD1310624; Tumor antigen CML66. |
| The NUDCD1 gene encodes the 583 amino acid CML66 protein which demonstrates expression in a variety of solid tumor cell lines and leukemias. Expression of CML66 in normal tissues is restricted to testis and heart. The CML66 antibody is found in sera of 18-38% of patients with lung cancer, melanoma or prostate cancer. These findings indicate that CML66 may be immunogenic in a wide variety of malignancies and may be a target for antigen-specific immunotherapy. A short isoform of CML66, designated CML66-S, is a product of alternative splicing. CML66-S has the same C-terminus as full-lenghth CML66 (also designated CML66-L), but has a unique N-terminus. CML66-S shows predominant expression in testis, and is also expressed in very low levels in tumor cells, while CML66 is expressed in tumor cells and testis. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz